- Home
- VIR vs OFG Comparison
VIR vs OFG Comparison
Compare VIR & OFG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VIR | OFG |
|---|---|---|
| Founded | 2016 | 1964 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2019 | 2012 |
Fundamental Metrics
Financial Performance| Metric | VIR | OFG |
|---|---|---|
| Price | $9.63 | $45.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | $19.43 | ★ $45.17 |
| AVG Volume (30 Days) | ★ 1.4M | 196.2K |
| Earning Date | 05-06-2026 | 04-21-2026 |
| Dividend Yield | N/A | ★ 3.12% |
| EPS Growth | ★ 17.49 | 8.27 |
| EPS | N/A | ★ 1.26 |
| Revenue | ★ $68,556,000.00 | N/A |
| Revenue This Year | $270.22 | $11.56 |
| Revenue Next Year | N/A | $1.29 |
| P/E Ratio | ★ N/A | $36.33 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.16 | $35.71 |
| 52 Week High | $11.66 | $46.85 |
Technical Indicators
Market Signals| Indicator | VIR | OFG |
|---|---|---|
| Relative Strength Index (RSI) | 51.92 | 56.60 |
| Support Level | $8.48 | $44.61 |
| Resistance Level | $10.29 | $45.63 |
| Average True Range (ATR) | 0.42 | 0.94 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 71.95 | 71.43 |
Price Performance
Historical ComparisonAbout VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
About OFG OFG Bancorp
OFG Bancorp is a financial holding company, through its subsidiaries provides banking and financial services. It operates through three segments namely Banking, Wealth Management, and Treasury. It serves to clients such as commercial, consumer, auto, and mortgage lending, checking and savings accounts, financial planning, insurance, financial services, and investment brokerage, and corporate and individual trust and retirement services. The company derives maximum revenue from Banking Segment. It provides services in the region of Puerto Rico.